A study recently reported a reduction in hamartomas in patients with PHTS after rapamycin treatment, suggesting that patients with disorders in the PTEN hamartoma tumor syndrome spectrum might respond to therapies designed to inhibit the PI3-K/mTOR pathway (Marsh D. J. et al., 2008). The gene discussed is MTOR; the disease is PTEN hamartoma tumor syndrome.